Skip to contentA
aTYR PHARMA INC
A
ATYRaTYR PHARMA INC Q1 2024 · 10-Q
Revenue$235.00K$235.00K— vs Q1 2023 Net Income-$15.49M-$15.49MN/M vs Q1 2023 EPS Diluted-$0.23-$0.23N/M vs Q1 2023 Operating Income-$16,636,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR
Free Cash Flowderived-$22,397,000N/M Margins · derivedOperating margin-7079.1%
Net margin-6591.9%
ended Mar 31, 2024 · filed May 2, 2024 · 32 d after period end